Injury claims from asbestos, silica, mold and other toxic exposures are an ongoing threat to California businesses and insurers. Asbestos litigation is the nation's most enduring mass civil litigation. As litigation frameworks and standards have evolved during decades of lawsuits, Archer Norris has established itself as a powerful presence in California asbestos and toxic torts litigation.
Defending High Volume and High Risk Claims
We have defended thousands of asbestos-related claims alone - and regularly handle a wide variety of toxic exposure lawsuits. Our clients' goals include early case dismissal, cost efficient settlement and defense jury verdicts. Archer Norris evaluates cases strategically and efficiently with an eye towards aggressively defending claims of liability, reducing damages to nominal amounts and clearing threats of future litigation.
Reducing Litigation in Asbestos and Contaminants Exposure
Our experience includes handling claims involving asbestosis, lung cancer, mesothelioma, silicosis, and leukemia filed against contractors, subcontractors, shipyards, railroads and manufacturers. We have conducted more than 20 winning trials in this area in just the past five years.
Additional health hazard substances we regularly manage includes benzyne, toluene, tetrachloroethylene (TCE), PCE, and hydrocarbons. We also defend lawsuits involving Legionnaires’ Disease, blood and foodborne illnesses such as E.coli, welding fumes and manganese injuries, and mold exposure.
Expert Network for Refuting Causation Misconceptions
Scientific and technical evidence are pivotal in toxic exposure cases. We access our network of world-class experts in medicine, science and manufacturing - a resource that provides a distinct advantage when defending clients.
We know that following a well-worn settlement script will not achieve our clients' goals. Archer Norris attorneys skillfully devise alternative theories to challenge the plaintiffs' commonly held assumptions and obtain favorable case outcomes in settlement negotiations and at trial.